Article Text

Download PDFPDF
▼Reboxetine - another new antidepressant
  • Relevant BNF section: 4.3.4


▼Reboxetine (Edronax - Pharmacia & Upjohn) is a new antidepressant drug introduced last year for the acute treatment and, in patients who respond, the maintenance treatment of depression. It is marketed as a "new selective noradrenaline reuptake inhibitor" (or 'NARI'). The manufacturer claims that reboxetine "not only lifts depressed mood" but also "helps restore social interaction", with "significantly better outcome in terms of social functioning" than fluoxetine. We assess these claims and consider the place of reboxetine in therapy.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

  • Relevant BNF section: 4.3.4

View Full Text